A randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on the duration of mechanical ventilation.

St Vincents Hospital Melbourne0 个研究点目标入组 50 人开始时间: 2020年4月27日最近更新: 2023年10月9日

试验速览

暂无简介。

•Age 18 years or older
•In ICU or scheduled for transfer to ICU
•Endotracheal tube in place
•Intubated yesterday or today
•PaO2 to FIO2 ratio less than or equal to 300 while intubated
•Acute opacities not fully explained by effusions, lobar/lung collapse and nodules, affecting at least one lung quadrant on chest X-ray or CT
•The acute opacities on chest X-ray or CT are most likely due to COVID-19
•There is a PCR positive sample for SARS-CoV-2 within the past 21 days or there are results pending or further testing is planned

•Enrolled in another clinical trial that is unapproved for co-enrolment
•Heparin allergy or heparin-induced thrombocytopaenia
•APTT > 120 seconds and this is not due to anticoagulant therapy
•Platelet count < 20 x 10^9 per L
•Pulmonary bleeding
•Uncontrolled bleeding
•Pregnant or might be pregnant
•Receiving or about to commence ECMO or HFOV
•Myopathy, spinal cord injury, or nerve injury or disease with a likely prolonged incapacity to breathe independently e.g. Guillain-Barre syndrome
•Acute brain injury that may result in long-term disability
•Usually receives home oxygen
•Dependent on others for personal care due to physical or cognitive decline
•Death is imminent or inevitable within 24 hours
•The clinical team would not be able to set up the study nebuliser and ventilator circuit as required including with active humidification
•Clinician objection

发起方

St Vincents Hospital Melbourne